Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Copanlisib in Metastatic Triple Negative Breast Cancer
NCT04345913Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of copanlisib in triple-negative breast cancer (TNBC) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 28 days, Recommended Phase 2 Dose up to 28 days and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04345913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345913.